Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Change in Acquisitions & Divestments: 2023-2025

Historic Change in Acquisitions & Divestments for Contineum Therapeutics (CTNM) over the last 3 years, with Sep 2025 value amounting to $33.7 million.

  • Contineum Therapeutics' Change in Acquisitions & Divestments fell 20.35% to $33.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $166.8 million, marking a year-over-year increase of 16.37%. This contributed to the annual value of $157.2 million for FY2024, which is 104.87% up from last year.
  • Per Contineum Therapeutics' latest filing, its Change in Acquisitions & Divestments stood at $33.7 million for Q3 2025, which was down 14.44% from $39.4 million recorded in Q2 2025.
  • Contineum Therapeutics' 5-year Change in Acquisitions & Divestments high stood at $48.7 million for Q1 2025, and its period low was $12.6 million during Q3 2023.
  • Its 3-year average for Change in Acquisitions & Divestments is $32.3 million, with a median of $33.7 million in 2025.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first spiked by 235.53% in 2024, then dropped by 20.35% in 2025.
  • Contineum Therapeutics' Change in Acquisitions & Divestments (Quarterly) stood at $31.3 million in 2023, then soared by 44.03% to $45.1 million in 2024, then decreased by 20.35% to $33.7 million in 2025.
  • Its Change in Acquisitions & Divestments was $33.7 million in Q3 2025, compared to $39.4 million in Q2 2025 and $48.7 million in Q1 2025.